{"filing":{"accession_number":"0001193125-26-251548","cik":"0001609809","ticker":"MCRB","company_name":"Seres Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-01","report_date":null,"primary_document":"d100982d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526251548/d100982d8k.htm"},"events":[{"id":2470,"run_id":2140,"accession_number":"0001193125-26-251548","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Hans-Juergen Woerle, M.D., Ph.D. resigned from his position as a board member of Seres Therapeutics effective May 31, 2026. The disclosure explicitly states the departure and its effective date, with a standard representation that the resignation was not due to disagreement. Board departures are material events affecting the composition of the company's governance.","company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","filing_date":"2026-06-01","items":[{"id":3167,"accession_number":"0001193125-26-251548","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Hans-Juergen Woerle, M.D., Ph.D. resigned from his position as a board member of Seres Therapeutics effective May 31, 2026. The disclosure explicitly states the departure and its effective date, with a standard representation that the resignation was not due to disagreement. Board departures are material events affecting the composition of the company's governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:41:05.417948+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":3167,"accession_number":"0001193125-26-251548","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Hans-Juergen Woerle, M.D., Ph.D. resigned from his position as a board member of Seres Therapeutics effective May 31, 2026. The disclosure explicitly states the departure and its effective date, with a standard representation that the resignation was not due to disagreement. Board departures are material events affecting the composition of the company's governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-02T02:41:05.417948+00:00","company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","filing_date":"2026-06-01"}]}